Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
Invest New Drugs. 2019 Aug;37(4):796.
doi: 10.1007/s10637-019-00746-y.
1 Department of Convergence Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea.
2 Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea.
3 Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, South Korea.
4 Department of Internal Medicine & Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea.
5 Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, South Korea.
6 PiMedBio, Inc., Seoul, 06367, South Korea.
7 Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, South Korea. cskim@amc.seoul.kr.
The blots of control and docetaxel for caspase-9, caspase-3, caspase-8, Bcl-XL, and tubulin in the Figure 4f were reused from Figure 4 of our previous paper published in Journal of Urology in 2010 ( https://doi.org/10.1016/j.juro.2010.07.035 ).